Velcade (Bortezomib) - Summary

VELCADE SUMMARY

VELCADE® (bortezomib) for Injection

VELCADE^® (bortezomib) for Injection is an antineoplastic agent available for intravenous injection (IV) use only. Each single dose vial contains 3.5 mg of bortezomib as a sterile lyophilized powder. Inactive ingredient: 35 mg mannitol, USP.

VELCADE^® (bortezomib) for Injection is indicated for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy.

The effectiveness of VELCADE is based on response rates (CLINICAL STUDIES section). There are no controlled trials demonstrating a clinical benefit, such as an improvement in survival.

VELCADE NEWS HIGHLIGHTS

Media Articles Related to Velcade (Bortezomib)

New England Journal Of Medicine Publishes Phase III Results Of VELCADE(R) (Bortezomib) For Injection In Previously Untreated Multiple Myeloma Patients
Source: Blood / Hematology News From Medical News Today [2008.08.29]

Bortezomib (Velcade) in Combo Scores For Initial Myeloma Treatment
Source: MedPage Today Hematology/Oncology [2008.08.27]

Human Genome Sciences Reports Initial Results Of Randomized Phase 2 Trial Of HGS-ETR1 In Combination With Bortezomib In Advanced Multiple Myeloma
Source: Blood / Hematology News From Medical News Today [2008.09.04]

Combination Therapy Helps to Combat Myeloma (HealthDay)
Source: Y! Health News Search RSS Feed [2008.08.27]

MMRC Partners With Celgene Corporation On Phase I/II Trial Of Pomalidomide In Relapsed And Refractory Multiple Myeloma Patients
Source: Blood / Hematology News From Medical News Today [2008.08.26]

more>>

Published Studies Related to Velcade (Bortezomib)

Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. [2008.05.10]

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. [2008.04]

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. [2007.09.01]

A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. [2007.03.15]

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. [2006.09.01]

more>>

Clinical Trials Related to Velcade (Bortezomib)

Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma [Recruiting]

Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma [Active, not recruiting]

Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma [Active, not recruiting]

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma [Active, not recruiting]

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy [Completed]

more>>